Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TARS Tarsus Pharmaceuticals, Inc.

Post-Mkt 12-12 18:04:26 EST

81.35

-0.35

-0.43%

盘后81.35

+0.000.00%

17:59 EST

High83.34	Low80.51	Vol452.64K
Open82.33	D1 Closing81.70	Amplitude3.46%
Mkt Cap3.45B	Tradable Cap2.47B	Total Shares42.45M
T/O37.02M	T/O Rate1.49%	Tradable Shares30.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TARS","market":"US","secType":"STK","nameCN":"Tarsus Pharmaceuticals, Inc.","latestPrice":81.35,"timestamp":1765573200000,"preClose":81.7,"halted":0,"volume":452638,"hourTrading":{"tag":"盘后","latestPrice":81.35,"preClose":81.35,"latestTime":"17:59 EST","volume":28099,"amount":2285853.65,"timestamp":1765580358797},"delay":0,"floatShares":30351553,"shares":42449105,"eps":-1.992481,"marketStatus":"Post-Mkt","change":-0.35,"latestTime":"12-12 18:04:26 EST","open":82.33,"high":83.335,"low":80.51,"amount":37018285.472512,"amplitude":0.034578,"askPrice":82.94,"askSize":24,"bidPrice":79.78,"bidSize":25,"shortable":3,"etf":0,"ttmEps":-1.992481,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1765587600000},"marketStatusCode":4,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":81.7,"preHourTrading":{"tag":"盘前","latestPrice":81.81,"preClose":81.7,"latestTime":"07:03 EST","volume":1646,"amount":134737.01704,"timestamp":1765541009788},"postHourTrading":{"tag":"盘后","latestPrice":81.35,"preClose":81.35,"latestTime":"17:59 EST","volume":28099,"amount":2285853.65,"timestamp":1765580358797},"volumeRatio":0.953241,"impliedVol":0.5957,"impliedVolPercentile":0.588},"requestUrl":"/m/hq/s/TARS","defaultTab":"news","newsList":[{"id":"2590328152","title":"Tarsus Pharmaceuticals Initiated at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2590328152","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590328152?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:28","pubTimestamp":1765297680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 11:28 ET (16:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"gpt_icon":0},{"id":"2586188884","title":"Tarsus Pharmaceuticals to Join BTIG Annual Ophthalmology Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2586188884","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586188884?lang=en_us&edition=fundamental","pubTime":"2025-11-25 05:30","pubTimestamp":1764019811,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals Inc. will participate in a fireside chat at the BTIG 5th Annual Ophthalmology Day on Monday, December 1st, at 10:45 a.m. PT / 1:45 p.m. ET. A live webcast and replay of the event will be available on the Tarsus website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on November 24, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL3Z2xph:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210150020.SGD","LU2095319765.USD","BK4007","BK4585","IE00BKPKM429.USD","TARS","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ"],"gpt_icon":0},{"id":"2585315680","title":"Tarsus Pharmaceuticals Initiated at Outperform by Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2585315680","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585315680?lang=en_us&edition=fundamental","pubTime":"2025-11-21 00:20","pubTimestamp":1763655600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2025 11:20 ET (16:20 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MFG","TARS"],"gpt_icon":0},{"id":"2584135056","title":"Mizuho Initiates Tarsus Pharmaceuticals at Outperform With $100 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2584135056","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584135056?lang=en_us&edition=fundamental","pubTime":"2025-11-20 19:50","pubTimestamp":1763639403,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) has an average rating of buy and mean price target of $86.11, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TARS","MFG"],"gpt_icon":0},{"id":"2584138625","title":"Tarsus Pharmaceuticals Inc : Mizuho Initiates Coverage With Outperform Rating; Target Price $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2584138625","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584138625?lang=en_us&edition=fundamental","pubTime":"2025-11-20 18:48","pubTimestamp":1763635699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nFWN3WW0S8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TARS","BK4007"],"gpt_icon":0},{"id":"2584138790","title":"Tarsus Pharmaceuticals initiated with an Outperform at Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2584138790","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584138790?lang=en_us&edition=fundamental","pubTime":"2025-11-20 18:45","pubTimestamp":1763635519,"startTime":"0","endTime":"0","summary":"Mizuho initiated coverage of Tarsus Pharmaceuticals (TARS) with an Outperform rating and $100 price target Tarsus is a commercial stage, ophthalmol...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-initiated-with-an-outperform-at-mizuho-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tarsus-pharmaceuticals-initiated-with-an-outperform-at-mizuho-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MFG","TARS"],"gpt_icon":0},{"id":"2583511637","title":"Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising Revenue Guidance and Narrowing Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2583511637","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583511637?lang=en_us&edition=fundamental","pubTime":"2025-11-14 02:37","pubTimestamp":1763059028,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals recently reported third-quarter 2025 revenue of US$118.7 million and reduced its net loss compared to the previous year, while also providing fourth-quarter annual revenue guidance in the range of US$440 million to US$445 million.\nA key insight from these announcements is that the company's financial outlook and operational performance have shown substantial improvement, reflecting both strong product demand and narrowing losses.\nWe'll examine how Tarsus...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/why-tarsus-pharmaceuticals-tars-is-up-97-after-raising-reven","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/why-tarsus-pharmaceuticals-tars-is-up-97-after-raising-reven","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2581088482","title":"Tarsus to Participate in Upcoming Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2581088482","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581088482?lang=en_us&edition=fundamental","pubTime":"2025-11-06 06:05","pubTimestamp":1762380300,"startTime":"0","endTime":"0","summary":"IRVINE, Calif., Nov.  05, 2025   -- Tarsus Pharmaceuticals, Inc. , today announced that management plans to participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, MA on Tuesday, November 11th, at 11:30 a.m. PT / 2:30 p.m. ET. Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care, dermatology, and infectious disease prevention. XDEMVY  0.25% is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3182061/0/en/Tarsus-to-Participate-in-Upcoming-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"gpt_icon":0},{"id":"2581772997","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2581772997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581772997?lang=en_us&edition=fundamental","pubTime":"2025-11-06 00:11","pubTimestamp":1762359073,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tarsus Pharmaceuticals (TARS – Research Report), Mic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-52?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-52?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4581","BLSH","HCSG","XBI","XLV","BK4585","BK4588","BK4112","TARS","BK4137","LU0029874061.USD","LU0128526141.USD","LABU"],"gpt_icon":0},{"id":"2581779761","title":"Tarsus Pharmaceuticals Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2581779761","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581779761?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:15","pubTimestamp":1762355700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 10:15 ET (15:15 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"gpt_icon":0},{"id":"2581769279","title":"Tarsus Pharmaceuticals Q3 EPS $(0.30) Beats $(0.38) Estimate, Sales $118.697M Beat $115.222M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581769279","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581769279?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:06","pubTimestamp":1762290363,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.38) by 21.88 percent. This is a 50.82 percent increase over losses of $(0.61) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48637049/tarsus-pharmaceuticals-q3-eps-0-30-beats-0-38-estimate-sales-118-697m-beat-115-222m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tarsus Pharmaceuticals Q3 EPS $(0.30) Beats $(0.38) Estimate, Sales $118.697M Beat $115.222M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"gpt_icon":0},{"id":"2581769126","title":"Tarsus Pharmaceuticals Q3 EPS USD -0.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2581769126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581769126?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:05","pubTimestamp":1762290310,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLX4F3590:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TARS"],"gpt_icon":0},{"id":"2581358761","title":"Press Release: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements","url":"https://stock-news.laohu8.com/highlight/detail?id=2581358761","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581358761?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:05","pubTimestamp":1762290300,"startTime":"0","endTime":"0","summary":"Delivered quarterly XDEMVY net sales of approximately $119 million, up approximately 147% year-over-year. Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial momentum. Management to host conference call today, November 4, 2025, at 1:30 p.m. PT / 4:30 p.m. ET. IRVINE, Calif., Nov. 04, 2025  -- Tarsus Pharmaceuticals, Inc. , today announced financial results for the third quarter ended September 30, 2025.\"Our third quarter results, highlighted by nearly $119 million in XDEMVY sales, reflect the strength of our commercial model, the scale of engagement across eye care, and the impact we're having on patients,\" said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. \"We've established a new category in eye care, and XDEMVY is now one of the best-selling prescription eye drops. Simultaneously, we are expanding our pipeline with more category-creating programs like ocular rosacea -- another widespread condition ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","BK4588","BK4118","DB","BK4007","OR","BK4232","BK4022","TARS","BK4585","BK4566","BK4552","R"],"gpt_icon":0},{"id":"2580420419","title":"Tarsus Pharmaceuticals Inc  expected to post a loss of 35 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2580420419","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580420419?lang=en_us&edition=fundamental","pubTime":"2025-11-01 05:02","pubTimestamp":1761944563,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals Inc  expected to post a loss of35cents a share - Earnings Preview Tarsus Pharmaceuticals Inc TARS.OQ TARS.O is expected to  show a rise in quarterly revenue when it reports  res","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC2EE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TARS"],"gpt_icon":0},{"id":"2579232997","title":"Tarsus Pharmaceuticals Inc. to Release Third Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2579232997","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579232997?lang=en_us&edition=fundamental","pubTime":"2025-10-29 05:00","pubTimestamp":1761685215,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals Inc. will report its third quarter 2025 financial results on Tuesday, November 4, 2025. Results will be released via a live webcast, which can be accessed at Participants may access the webcast here.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tarsus Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on October 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDLM3lNk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","TARS","BK4112","LU2095319765.USD","NDAQ","IE00BKPKM429.USD","BK4588","BK4007","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","LU0314104364.USD"],"gpt_icon":0},{"id":"2576803853","title":"Tarsus Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2576803853","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576803853?lang=en_us&edition=fundamental","pubTime":"2025-10-20 18:49","pubTimestamp":1760957340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TARS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 06:49 ET (10:49 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TARS"],"gpt_icon":0},{"id":"2576830668","title":"Tarsus Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $88 From $72","url":"https://stock-news.laohu8.com/highlight/detail?id=2576830668","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576830668?lang=en_us&edition=fundamental","pubTime":"2025-10-20 18:10","pubTimestamp":1760955047,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nAZN4OLWB3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TARS"],"gpt_icon":0},{"id":"2574195554","title":"Tarsus Pharmaceuticals (TARS): Evaluating Valuation After Xdemvy’s Strong Sales Growth and New Pipeline Announcements","url":"https://stock-news.laohu8.com/highlight/detail?id=2574195554","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574195554?lang=en_us&edition=fundamental","pubTime":"2025-10-10 01:18","pubTimestamp":1760030327,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) shares jumped after stronger-than-expected sales growth from Xdemvy, its prescription treatment for Demodex blepharitis. The company also announced it is preparing mid-stage trials for new pipeline therapies.\nSee our latest analysis for Tarsus Pharmaceuticals.\nTarsus Pharmaceuticals has been on an impressive run, with a 22.6% share price return over the past month and more than doubling total shareholder return at 100.8% in the last year. Recent surges reflect...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-tars-evaluating-valuation-after-xdemv","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tars/tarsus-pharmaceuticals/news/tarsus-pharmaceuticals-tars-evaluating-valuation-after-xdemv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TARS"],"gpt_icon":0},{"id":"2574696851","title":"Ionis, Jazz Named Top Picks as US Biopharma Heads Into Steady Q3, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2574696851","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574696851?lang=en_us&edition=fundamental","pubTime":"2025-10-09 22:55","pubTimestamp":1760021747,"startTime":"0","endTime":"0","summary":"US biopharmaceutical companies are heading into a seasonally mixed Q3 with limited earnings surprises expected, while the investor focus shifts to upcoming clinical and corporate catalysts, BofA said Thursday in a research note previewing Q3 results.The firm said Ionis Pharmaceuticals  and Jazz Pharmaceuticals  were its top picks heading into year-end, citing strong clinical pipelines and event-driven upside.BofA adjusted several price objectives, raising Jazz to $230 from $225, Liquidia  to $37 from $35, Tarsus  to $85 from $80, and Teva  to $24 from $22, while trimming Amphastar  to $31 from $32.The analysts said they do not expect major Q3 beats or misses but highlighted upcoming events such as Jazz's phase 3 zanidatamab data in gastric cancer, Ionis' trial updates, and Teva's potential TAPI divestiture announcement.BofA maintained buy ratings on Ionis, Jazz, Liquidia, Tarsus, and Teva.Price: 70.11, Change: +0.15, Percent Change: +0.21","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AMPH","IONS","LQDA","LU0320765992.SGD","BK4584","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4007","BK4557","TEVA","TARS","BK4566","BK4596","BK4532","LU0109394709.USD","IE00BN0W2V16.EUR","BK4585","BK4139","BK4533","BK4588","BK4559","JAZZ","LU0823416689.USD","LU0889565916.HKD","LU1983299246.USD"],"gpt_icon":0},{"id":"2574163013","title":"BofA Ups Price Target on Tarsus Pharmaceuticals to $85 From $80","url":"https://stock-news.laohu8.com/highlight/detail?id=2574163013","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574163013?lang=en_us&edition=fundamental","pubTime":"2025-10-09 22:01","pubTimestamp":1760018468,"startTime":"0","endTime":"0","summary":"Tarsus Pharmaceuticals (TARS) has an average rating of buy and mean price target of $74.43, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TARS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tarsusrx.com","stockEarnings":[{"period":"1week","weight":-0.0016},{"period":"1month","weight":0.0801},{"period":"3month","weight":0.6552},{"period":"6month","weight":0.998},{"period":"1year","weight":0.5669},{"period":"ytd","weight":0.4755}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1544},{"period":"1year","weight":0.1345},{"period":"ytd","weight":0.1759}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tarsus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.039062},{"month":2,"riseRate":0.2,"avgChangeRate":0.010659},{"month":3,"riseRate":0.2,"avgChangeRate":-0.047875},{"month":4,"riseRate":0.6,"avgChangeRate":0.02077},{"month":5,"riseRate":0.6,"avgChangeRate":-0.033136},{"month":6,"riseRate":0.4,"avgChangeRate":-0.04436},{"month":7,"riseRate":0.4,"avgChangeRate":-0.024485},{"month":8,"riseRate":0.8,"avgChangeRate":0.123751},{"month":9,"riseRate":0.8,"avgChangeRate":0.033781},{"month":10,"riseRate":0.8,"avgChangeRate":0.135195},{"month":11,"riseRate":0.666667,"avgChangeRate":0.092511},{"month":12,"riseRate":0.666667,"avgChangeRate":0.121736}],"exchange":"NASDAQ","name":"Tarsus Pharmaceuticals, Inc.","nameEN":"Tarsus Pharmaceuticals, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tarsus Pharmaceuticals, Inc.,TARS,Tarsus Pharmaceuticals, Inc.股票,Tarsus Pharmaceuticals, Inc.股票老虎,Tarsus Pharmaceuticals, Inc.股票老虎国际,Tarsus Pharmaceuticals, Inc.行情,Tarsus Pharmaceuticals, Inc.股票行情,Tarsus Pharmaceuticals, Inc.股价,Tarsus Pharmaceuticals, Inc.股市,Tarsus Pharmaceuticals, Inc.股票价格,Tarsus Pharmaceuticals, Inc.股票交易,Tarsus Pharmaceuticals, Inc.股票购买,Tarsus Pharmaceuticals, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tarsus Pharmaceuticals, Inc.(TARS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tarsus Pharmaceuticals, Inc.(TARS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}